GNPX

Genprex, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website genprex.com
Employees(FY) 31
ISIN US3724462037

Performance

+4.94%

1W

+10.87%

1M

-42.05%

3M

-73.25%

6M

-72.28%

YTD

-91.74%

1Y

Profile

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) that is in Phase 1/2 and 2 clinical trials to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002 for the treatment of type 1 diabetes, and GPX-003 for the treatment of type 2 diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

Advanced Technical Analysis

Technical Analysis of GNPX 2024-05-10

Overview:

In analyzing the technical indicators for GNPX over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days.

Trend Analysis:

Moving Averages (MA): The 5-day Moving Average (MA) has been fluctuating around the c...

See more ...

Recent News & Updates

2024-05-14 16:42
Genprex dosing subjects in trial of combination therapy for small-cell lung cancer(Yahoo Finance)
2024-05-13 20:31
Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa Immunogene Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer(Prnewswire)
2024-05-12 20:31
Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors(Prnewswire)
2024-05-08 06:08
Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney Varner(Prnewswire)
2024-05-06 21:15
Sidoti Events, LLC's Virtual May Micro-Cap Conference(Accesswire)
2024-04-30 20:31
Genprex to Present and Participate at Upcoming May Investor and Industry Conferences(Prnewswire)
2024-04-08 20:31
Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting(Prnewswire)
2024-04-03 20:57
Genprex (GNPX) Expands SCLC Study of Key Candidate, Stock Up(Yahoo Finance)
2024-04-03 20:57
Genprex (GNPX) Expands SCLC Study of Key Candidate, Stock Up(Zacks)
2024-04-02 20:31
Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer(Prnewswire)
2024-04-01 20:31
Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex Delivery System(Prnewswire)
2024-03-22 04:10
Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules(Prnewswire)
2024-03-19 01:24
Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules(Prnewswire)
2024-03-18 20:36
Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules(Prnewswire)
2024-03-11 21:01
Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers(Prnewswire)
2024-03-05 19:30
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting(Prnewswire)
2024-02-06 19:15
Genprex Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators(Prnewswire)
2024-02-05 18:30
Genprex to Present at Upcoming BIO CEO & Investor Conference(Prnewswire)
2024-02-04 18:30
Genprex Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa Therapy in Combination with Tagrisso to Treat Non-Small Cell Lung Cancer(Prnewswire)
2024-01-30 19:42
Genprex Announces 1-for-40 Reverse Stock Split Effective February 2, 2024(Prnewswire)
2024-01-04 18:00
Genprex Provides Business Update and Outlook for 2024(Prnewswire)
2023-11-22 19:30
Genprex Granted Orphan Drug Designation in Small Cell Lung Cancer(Yahoo Finance)
2023-11-02 21:00
Genprex to Present at BIO-Europe 2023(Yahoo Finance)
2023-10-31 19:30
Genprex to Present at BIO-Europe 2023 Conference(Prnewswire)
2023-10-20 03:00
Genprex Schedules, Hosts Virtual Key Opinion Leader Event(Yahoo Finance)
2023-10-19 19:30
Genprex to Host a Virtual Key Opinion Leader Event on 'Bringing Gene Therapy to the Fight Against Lung Cancers'(Prnewswire)
2023-10-05 21:00
Genprex to Unveil Encouraging Data on REQORSA(R) at AACR-NIH-EORTC Conference(Yahoo Finance)
2023-10-04 00:00
Genprex to Present Data on the Use of REQORSA for the Treatment of Lung Cancers at 2023 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics(Prnewswire)
2023-09-20 20:30
Genprex Inc. (NASDAQ: GNPX) Receives Orphan Drug Designation for Immunogene Therapy for Treatment of SCLC(Yahoo Finance)
2023-09-18 21:00
Genprex Looks Forward to Acclaim-3 Trial on Heels of Receipt of FDA FTD and ODD Designations(Yahoo Finance)

Page 1 of 4

previousnext